---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-026904"
form_type: "8-K"
ticker: "LYEL"
cik: "0001806952"
company_name: "Lyell Immunopharma, Inc."
filed_at: "2022-10-24T23:59:59+00:00"
generated_at: "2026-06-23T01:42:07.946156+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# GSK terminates collaboration with Lyell; NY-ESO-1 programs discontinued

## Summary
- GSK provided termination notice Oct 24, 2022, effective Dec 24, 2022; ends development of LYL132 and LYL331 incorporating Lyell's technologies.
- Termination follows GSK's strategic review after lete-cel NSCLC data; not based on safety/efficacy of Lyell's programs.
- Lyell discontinuing further work on these programs; minimal operational impact as GSK ran them; no patients treated with LYL132.
- Cash, cash equivalents and marketable securities expected to fund working capital into 2025; Glaxo Group remains significant stockholder.
- Lyell received $250M upfront/equity in 2019 collaboration; would have been eligible for milestones and royalties.

## SEC filing metadata
- accession: 0001628280-22-026904
- form_type: 8-K
- ticker: LYEL
- cik: 0001806952
- company_name: Lyell Immunopharma, Inc.
- filed_at: 2022-10-24T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1806952/000162828022026904/0001628280-22-026904-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1806952/000162828022026904/lyel-20221024.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-026904
- JSON: https://secwatch.observer/filing/0001628280-22-026904.json
- Plain text: https://secwatch.observer/filing/0001628280-22-026904.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.